[Management of 315neutropenic febrile episodes in a cancer center]
- PMID: 19062208
- DOI: 10.1016/j.medmal.2008.10.014
[Management of 315neutropenic febrile episodes in a cancer center]
Abstract
Management of febrile neutropenic patients is described in guidelines. Each cancer center can adapt these according to its local bacterial ecology. We present a retrospective study made in a cancer center from 2001 to 2003.
Method: Three hundred and fifteen febrile neutropenic episodes after chemotherapy (66% for solid tumor) were analysed.
Results: For 279 episodes, no antibiotic therapy was given before admission. Clinical or radiological manifestations occurred in 46%; microbiologically documented infections by hemocultures in 28% (Gram positive: 42%; Gram negative: 51%) and by puncture in 14% (Gram negative: 58%). The length of pyrexia was inferior to 7 days in 88% and neutropenia inferior 7 days in 80.8%. 79.7% of episodes were treated with one of the three antibiotic therapy recommended by the center (ceftriaxone+tobramycin; ceftriaxone+ciprofloxacin; ceftriaxone+ofloxacin); 13.3% were treated with an other therapy; 7% received no antibiotic therapy. 68.5% of patients treated with one of the three antibiotic therapies, became afebrile without changing the antibiotic protocol.
Conclusion: In our study, there were a majority of Gram negative bacteria except for Pseudomonas aeruginosa. The three antibiotic therapy recommended by the center (third generation cephalosporin+aminoglycosides or fluoroquinolones) were effective and glycopeptide was not necessary in first intention treatment.
Similar articles
-
Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.J Chemother. 1995 Jun;7 Suppl 2:103-10. J Chemother. 1995. PMID: 8622099 Clinical Trial.
-
Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey.Pediatr Hematol Oncol. 2006 Apr-May;23(3):217-29. doi: 10.1080/08880010500506719. Pediatr Hematol Oncol. 2006. PMID: 16517538
-
Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.Int J Antimicrob Agents. 2005 Dec;26 Suppl 2:S123-7; discussion S133-40. doi: 10.1016/j.ijantimicag.2005.08.001. Epub 2005 Oct 24. Int J Antimicrob Agents. 2005. PMID: 16249072
-
Antibiotic therapy for gram-negative bacteremia.Infect Dis Clin North Am. 1991 Dec;5(4):817-34. Infect Dis Clin North Am. 1991. PMID: 1783770 Review.
-
Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.Cancer. 2006 Oct 15;107(8):1743-51. doi: 10.1002/cncr.22205. Cancer. 2006. PMID: 16977651 Review.
Cited by
-
Pharmacogenetics-Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort.Front Pharmacol. 2021 Mar 10;12:602676. doi: 10.3389/fphar.2021.602676. eCollection 2021. Front Pharmacol. 2021. PMID: 33776761 Free PMC article.
-
Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change.Infect Drug Resist. 2010;3:53-61. doi: 10.2147/idr.s11413. Epub 2010 Jul 28. Infect Drug Resist. 2010. PMID: 21694894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical